Pyridostigmine chlorideProduct ingredient for Pyridostigmine
- Name
- Pyridostigmine chloride
- Drug Entry
- Pyridostigmine
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue.2 Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of physostigmine and neostigmine. By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.2,10,11 Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to neostigmine.10,11 In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve agents, notably during the Gulf War.3,4,11,12
Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. Possible dose forms have been expanded to include extended-release tablets, syrups, and injections, marketed under various brand and generic names.10,11
- Accession Number
- DBSALT002338
- Structure
- Synonyms
- Not Available
- UNII
- 45X1P9AO69
- CAS Number
- 7681-22-3
- Weight
- Average: 216.67
Monoisotopic: 216.0665554 - Chemical Formula
- C9H13ClN2O2
- InChI Key
- TYXYRYORUZYJDX-UHFFFAOYSA-M
- InChI
- InChI=1S/C9H13N2O2.ClH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1
- IUPAC Name
- 3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium chloride
- SMILES
- [Cl-].CN(C)C(=O)OC1=C[N+](C)=CC=C1
- External Links
- ChemSpider
- 175091
- Predicted Properties
Property Value Source Water Solubility 1.71 mg/mL ALOGPS logP -3.1 ALOGPS logP -3.5 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) 19.53 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 33.42 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 49.66 m3·mol-1 Chemaxon Polarizability 19.37 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon